Immix Biopharma, Inc. IMMX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -54.9%+90.8pp | -145.8%-41.4pp | -104.4%-51.5pp | -52.8%— | |
| Liquidity | |||||
| Current ratio | 10×+7.7× | 2.3×-3.0× | 5.3×-6.4× | 11.7×-78.3× | |
| Leverage | |||||
| Debt-to-equity | 0×-0.1× | 0.1×— | —— | —— | |
| Per Share | |||||
| Book value per share | $2.85+507% | $0.47-50.5% | $0.95-0.2% | $0.95-80.7% | |
| Valuation | |||||
| Market capitalization | $691.97M+1,008% | $60.52M-56.1% | $137.86M+355% | $30.29M-38.5% | |
| Price / book | 8.2×+1.7× | 4.6×-3.8× | 8.4×+6.1× | 2.3×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immix Biopharma, Inc.'s ratios come from?
- Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.